Archive for January 2024

The $1.4 billion deal closed in November last year, after becoming official over the summer. Read More

Vertex and bluebird bio, the companies behind the competing sickle-cell treatments approved in December, have provided new details in their plans to bring the treatments to patients in 2024. Read More

Massachusetts Gov. Maura Healey is expected to slash as much as $375 million in state spending on Monday, as the Democrat’s administration attempts to head off flagging tax collections, according to published reports. Read More

The deal to buy the maker of devices to treat urinary and bowel dysfunction represents a 23% premium over that company’s valuation as of Friday. Read More

Here are the five things you need to know in Boston business news to start your Monday, including Cerence CEO’s compensation, developers sought for city-owned land and the Mass. companies heading to CES, plus why we love a good streak. Read More

Also: Van Leeuwen Ice Cream is set to open its first two Boston-area locations, the next new Chinatown restaurant and Raising Cane’s will soon open its first downtown Boston location. Read More

Vertex has pressed pause on its Phase 1/2 study of its insulin-producing cell therapy for patients with type 1 diabetes following two patient deaths that the company said were unrelated to the drug. This is the second time Vertex’s progress on its diabetes drug has been paused. Read More

Will one downtown tower now going up score a big lease? Will another win approval at all? How about a groundbreaking for those long-awaited Seaport condos? Here’s what to keep an eye on this upcoming year. Read More

CES, which used to be called the Consumer Electronics Show, is scheduled to begin Tuesday this week in Las Vegas and run until Friday, Jan. 12. Read More